Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 8월 28

BioMarin Pharmaceutical Inc

BMRNNASDAQ
Trade with Public
Trade with Public
$64.40
-0.89-1.36%
마지막 업데이트: Aug 28, 10:41 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

BioMarin Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioMarin Pharmaceutical (BMRN).

Price Target Range — 9 Quarters

Analyst Consensus — 28 Analysts

20Buy
8Hold
Consensus RatingBuy# Analysts28Avg. Consensus PT$90Upside to Avg. PT+40.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$98
Aug 18, 2026HC Wainwright & Co.Mitchell S. KapoorPT CutNeutral$60→$59
More with Benzinga EdgeGet Access

Analyst Ratings News

This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
Avi Kapoor

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

PRO
BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.
Benzinga Newsdesk

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.
Vandana Singh

PRO
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $59

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $60 to $59.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved